Press release
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in
About this update from Incyte Corporation
[{"type":"text","content":"\n\nTotal net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y)\n\n\n\nJakafi® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023\n\n\n\nOpzelura® (ruxolitinib) cream net product revenues of $80 million (+384% Y/Y) in Q2'23; continued uptake in atopic dermatitis (AD) and vitiligo\n\n\n\nTwo pivotal studies in high potential programs met their primary endpoint: ruxolitinib cream in pediatric atopic dermatitis (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201)\n\n\n\n\nConference Call and Webcast Scheduled Today at 8:00 a.m. ET\n\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.\n\n\n\"We delivered a strong quarter with total net product revenues growing 25% year over year led by double-digit Jakafi® (ruxolitinib) growth and continued momentum from Opzelura® (ruxolitinib) cream in atopic dermatitis and vitiligo in the United States,\" said Hervé Hoppenot, Chief Executive Officer, Incyte. \"We continue to advance multiple programs in our pipeline, and recently announced positive topline results for two high potential programs, ruxolitinib cream in pediatric atopic dermatitis and axatilimab in chronic graft-versus-host disease.\"\n\n\nKey Product Sales Performance\n\n\nJakafi:\n\n\nNet product revenues for the quarter of $682 million:\n\n\n\nNet product revenues grew 14% compared with the second quarter of 2022, driven by strong underlying patient demand growth across all indications.\n\n\n\nChannel inventory at the end of the second quarter of 2023 returned to normal levels.\n\n\n\nOpzelura:\n\n\nNet product revenues for the quarter of $80 million:\n\n\n\nNet product revenues of $80 million grew 384% compared with the second quarter of 2022, driven by growth in patient demand and expansion in payer coverage as the launch in AD and vitiligo continues.\n\n\n\nOpzelura was approved in Europe for the treatment of nonsegmental vitiligo with facial involvement and is now available in Germany and Austria.\n\n\n\nPipeline Updates\n\n\nMPNs and GVHD – key highlights\n\n\nLIMBER (Leadership In MPNs and GVHD BEyond Ruxolitinib):\n\n\n\nAGAVE-201, a global pi...